Does elevated lipoprotein(a) promote atherothrombosis by interfering with fibrinolysis?

Clinical and Mechanistic Evidence

• Atherothrombotic Risk: Elevated Lipoprotein(a) [Lp(a)] is established as a causal, independent risk factor for atherothrombosis. Large-scale meta-analyses, such as those from the Emerging Risk Factors Collaboration involving over 126,000 participants, show a continuous, curvilinear relationship between Lp(a) levels and the risk of coronary heart disease and stroke. This risk is particularly significant at levels exceeding 50 mg/dL (approx. 125 nmol/L).
• Dual Pathogenicity: Lp(a) promotes cardiovascular events through two distinct but synergistic pathways:
  • Pro-atherogenic/Inflammatory: The LDL-like core and its associated Oxidized Phospholipids (OxPL) drive lipid deposition and vascular inflammation.
  • Pro-thrombotic: The apolipoprotein(a) [apo(a)] component interferes with the body's natural ability to dissolve blood clots (fibrinolysis).

Mechanistic Insights into Fibrinolysis Interference

• Plasminogen Mimicry: The apo(a) component of Lp(a) shares high structural homology with plasminogen, specifically the Kringle domains. This allows apo(a) to compete directly with plasminogen for lysine-binding sites on fibrin surfaces and endothelial cells.
• Competitive Inhibition: By occupying these sites, apo(a) prevents plasminogen and tissue-type plasminogen activator (tPA) from binding to the fibrin clot. This displacement reduces the local concentration of plasminogen available for conversion into the active enzyme, plasmin.
• Non-productive Complexes: When apo(a) binds within the fibrin-tPA-plasminogen assembly, it forms "non-productive" complexes. These complexes disrupt the necessary geometric orientation required for tPA to efficiently activate plasminogen, significantly slowing the rate of plasmin generation.
• Clot Architecture: Beyond enzymatic inhibition, Lp(a) alters the physical structure of the fibrin network, making it denser, less permeable, and more resistant to enzymatic breakdown. It also facilitates the inactivation of plasmin by alpha-2-antiplasmin, further suppressing fibrinolytic activity.

Practical Considerations for Patients

• Age and Sex Factors: For individuals over age 70, the cumulative exposure to elevated Lp(a) significantly increases the risk of atherothrombotic events. In post-menopausal women, changes in the hormonal milieu can further exacerbate vascular inflammation and potentially amplify the pro-thrombotic effects of Lp(a).
• Residual Risk: Even when LDL cholesterol is well-controlled with statins, elevated Lp(a) remains a potent driver of "residual cardiovascular risk." Current guidelines recommend at least a one-time measurement of Lp(a) to refine risk stratification, especially in patients with a strong family history or premature cardiovascular disease.

Bottom line

Elevated Lp(a) promotes atherothrombosis by combining the lipid-depositing properties of LDL with a unique, apo(a)-mediated inhibition of fibrinolysis. By competing with plasminogen for binding sites and forming inefficient catalytic complexes, Lp(a) prevents effective clot dissolution, leading to thrombus persistence and increased risk of heart attack and stroke.